StreetInsider.com News Articles

Biohaven Pharma (BHVN) PT Raised to $22 at RBC Capital

Fri, 23 Oct 2026 08:28:20 -0400

RBC Capital analyst Leonid Timashev raised the price target on Biohaven Pharma (NYSE: BHVN) to $22.00 (from $19.00) while maintaining a Sector Perform rating.

Biohaven Pharma (BHVN) January 17.5 calls active, share price up 23.9%

Thu, 22 Oct 2026 15:05:01 -0400

Biohaven Pharma (NYSE: BHVN) 30-day option implied volatility is at 86; compared to its 52-week range of 68 to 381. Call put ratio 2.6 call to 1 put with a focus on January 17.5 calls as share price up 23.9%.

Increasing unusual option volume: BHVN MAT CHGG TBT QGEN GFL ALLY LION GTM ZURA LBRT FITB OPTU KNX

Thu, 22 Oct 2026 09:59:21 -0400

Increasing unusual option volume: BHVN MAT CHGG TBT QGEN GFL ALLY LION GTM ZURA LBRT FITB OPTU KNX

Biohaven Pharma (BHVN) PT Raised to $48 at Baird

Thu, 22 Oct 2026 09:07:23 -0400

(Updated - October 22, 2026 9:07 AM EDT)

Baird analyst Brian Skorney raised the price target on Biohaven Pharma (NYSE: BHVN) to $48.00 (from $42.00) while maintaining a Outperform rating.

The analyst commented: "Positive on regulatory update. The disclosure of an accepted NDA for troriluzole (now branded as Vyglxia) with a 1Q27 PDUFA is a positive suprise. Although management hinted at a potential resurrection at their spring event, they have been relatively quiet on the topic since then. It appears they have been working in the background towards a resubmission and today's news includes two derisking events, submission and acceptance. We expect

Biohaven Pharma (BHVN) PT Raised to $48 at Baird

Thu, 22 Oct 2026 09:07:23 -0400

(Updated - October 22, 2026 9:07 AM EDT)

Baird analyst Brian Skorney raised the price target on Biohaven Pharma (NYSE: BHVN) to $48.00 (from $42.00) while maintaining a Outperform rating.

Biohaven stock surges 25% on FDA acceptance of drug filing

Thu, 22 Oct 2026 07:20:35 -0400

Investing.com -- Biohaven Ltd. shares jumped 25% Thursday after the Food and Drug Administration accepted the company’s resubmitted new drug application for troriluzole in spinocerebellar ataxia.

The FDA informed Biohaven that the resubmission for Vyglxia (troriluzole) in SCA has been accepted for review, according to a company filing with the Securities and Exchange Commission on October 22, 2026. The resubmission included new positive supportive analyses.

The FDA communicated that it considers the resubmission a complete response to the November 4, 2025 action letter and has assigned a user fee goal date in the first quarter of 2027. The

Biohaven stock surges 25% on FDA acceptance of drug filing

Thu, 22 Oct 2026 07:20:35 -0400

Investing.com -- Biohaven Ltd. shares jumped 25% Thursday after the Food and Drug Administration accepted the company’s resubmitted new drug application for troriluzole in spinocerebellar ataxia.

The FDA communicated that it considers the resubmission a complete response to the November 4, 2025 action letter and has assigned a user fee goal date in the first quarter of 2027. The

FDA accepts Biohaven's troriluzole NDA resubmission for rare disease

Thu, 22 Oct 2026 07:06:58 -0400

Biohaven Ltd. (NYSE: BHVN) announced that the U.S. Food and Drug Administration has accepted for review the company's new drug application resubmission for Vyglxia (troriluzole) in spinocerebellar ataxia (SCA).

The FDA determined that the resubmission constitutes a complete response to a November 4, 2025 action letter, according to a company statement. The resubmission included new supportive analyses.

The FDA has assigned a user fee goal date in the first quarter of 2027. The agency also plans to convene a meeting of the Peripheral and Central Nervous System Advisory Committee to gather input from external stakeholders. The date of that advisory committee meeting

FDA accepts Biohaven's troriluzole NDA resubmission for rare disease

Thu, 22 Oct 2026 07:06:58 -0400

The FDA determined that the resubmission constitutes a complete response to a November 4, 2025 action letter, according to a company statement. The resubmission included new supportive analyses.

FDA accepts Biohaven's troriluzole NDA resubmission for rare disease

Thu, 22 Oct 2026 07:06:58 -0400

The FDA determined that the resubmission constitutes a complete response to a November 4, 2025 action letter, according to a company statement. The resubmission included new supportive analyses.

Form 8-K Biohaven Ltd. For: Oct 22

Thu, 22 Oct 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20261022/27218763.html

Form 8-K Biohaven Ltd. For: Oct 08

Thu, 15 Oct 2026 17:19:00 -0400

si-local-file:///var/storage/secattach/20261015/27194190.html

Canaccord Reiterates Buy Rating on Biohaven Pharma (BHVN)

Fri, 09 Oct 2026 07:05:55 -0400

Canaccord analyst Sumant Kulkarni reiterated a Buy rating and $21.00 price target on Biohaven Pharma (NYSE: BHVN).

The analyst commented: "This morning (10/8), BHVN announced that it is out-licensing its 1300-series immunoglobulin G (IgG) degraders to Ono Pharmaceuticals in Japan, South Korea, Taiwan, and Association of Southeast Asian Nations (ASEAN) countries. For this, BHVN will receive $80mn in cash upfront, $20mn in milestones anticipated within a year after close, and ~20% royalties on eventual net sales in those regions. Recall the company's MoDE (molecular degrader of extracellular proteins) IgG degraders include lead-candidate BHV-1300 (in Phase 3 for Graves' disease), and BHV-1310/1320

Citi reiterates Buy rating on Biohaven Pharma after licensing deal

Thu, 08 Oct 2026 09:52:42 -0400

Citi analyst Samantha Semenkow reiterated a Buy rating and $17.00 price target on Biohaven Pharma (NYSE: BHVN) following the company's announcement of a regional licensing agreement with Ono Pharmaceutical.

Under the deal, Ono Pharmaceutical receives rights to Biohaven's MoDE pan-IgG degrader portfolio, including lead asset BHV-1300 and next-generation candidates BHV-1310 and BHV-1320, across Japan, South Korea, Taiwan, and ASEAN markets. Biohaven retains rights in the U.S., Europe, China, and the rest of the world.

The agreement provides Biohaven with up to $100M in near-term capital, consisting of an $80M upfront payment and a potential $20M milestone payment within one year, along with

Raymond James Reiterates Strong Buy Rating on Biohaven Pharma (BHVN)

Thu, 08 Oct 2026 09:50:54 -0400

Raymond James analyst Chris Raymond reiterated a Strong Buy rating and $30.00 price target on Biohaven Pharma (NYSE: BHVN).

The analyst comments "Remain Strong Buy rated on BHVN shares following the company’s announcement to outlicense the rights to IgG degrader BHV-1300 in Japan to Ono Pharma, which brings in $100M in near-term cash ($80M at deal close and $20M in a milestone payment anticipated within a year). We have written extensively about Biohaven’s financing overhang (see notes here and here), and we viewed Biohaven’s deal in August to out-license BHV-7000 to SK Biopharma as a key catalyst for reducing this overhang.

Biohaven licenses IgG degrader portfolio to Ono for $100M

Thu, 08 Oct 2026 04:00:24 -0400

Biohaven Ltd. (NYSE: BHVN) has entered into a licensing agreement with Ono Pharmaceutical Co., Ltd. (TYO: 4528), granting Ono an exclusive license to develop and commercialize Biohaven's MoDE pan IgG degrader portfolio in Japan, South Korea, Taiwan, and ASEAN member states, according to a press release.

Under the agreement, Biohaven will receive $80 million at closing and is eligible for an additional $20 million milestone payment anticipated within a year, bringing potential near-term payments to $100 million. Biohaven will also receive royalties of approximately 20% on net sales within the licensed territory. Biohaven retains all rights outside the licensed territory, including

Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease

Thu, 08 Oct 2026 04:00:00 -0400

Ono will obtain an exclusive license to develop and commercialize Biohaven's MoDE pan IgG degraders in Japan, South Korea, Taiwan, and ASEAN member states, led by BHV-1300 and including certain next-generation follow-on IgG degraders. Biohaven will receive up to $100 million in near-term payments, including $80 million upfront and eligible to receive

Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease

Thu, 08 Oct 2026 04:00:00 -0400

Ono will obtain an exclusive license to develop and commercialize Biohaven's MoDE pan IgG degraders in Japan, South Korea, Taiwan, and ASEAN member states, led by BHV-1300 and including certain next-generation follow-on IgG degraders. Biohaven will receive up to $100 million in near-term payments, including $80 million upfront and eligible to receive

Biohaven's BHV-1530 cancer drug selected for ENA 2026 presentation

Mon, 28 Sep 2026 07:31:29 -0400

Biohaven Ltd. (NYSE: BHVN) announced that Phase 1 clinical data on BHV-1530, its FGFR3-directed antibody-drug conjugate (ADC), have been selected for an oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026), scheduled for November 18-20, 2026, in Barcelona, Spain.
BHV-1530 uses Biohaven's proprietary topoisomerase I (TopoIx) payload and is being studied in the ongoing BHV1530-101 trial (NCT06874335), a Phase 1, first-in-human, open-label, multicenter study evaluating the drug as monotherapy and in combination with cemiplimab in adults with advanced or metastatic solid tumors. The presentation is scheduled for November 19, 2026, during Plenary Session 3.
According to

Biohaven's BHV-1530 cancer drug selected for ENA 2026 presentation

Mon, 28 Sep 2026 07:31:29 -0400

Biohaven Ltd. (NYSE: BHVN) announced that Phase 1 clinical data on BHV-1530, its FGFR3-directed antibody-drug conjugate (ADC), have been selected for an oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026), scheduled for November 18-20, 2026, in Barcelona, Spain.
BHV-1530 uses Biohaven's proprietary topoisomerase I (TopoIx) payload and is being studied in the ongoing BHV1530-101 trial (NCT06874335), a Phase 1, first-in-human, open-label, multicenter study evaluating the drug as monotherapy and in combination with cemiplimab in adults with advanced or metastatic solid tumors. The presentation is scheduled for November 19, 2026, during Plenary Session 3.
According to

Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026

Mon, 28 Sep 2026 07:30:00 -0400

Oral presentation selected: Phase 1 findings from the ongoing BHV1530-101 study will be featured in an oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026), a leading international forum for early-phase oncology drug development.

First-in-class FGFR3 ADC: BHV-1530

Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026

Mon, 28 Sep 2026 07:30:00 -0400

Oral presentation selected: Phase 1 findings from the ongoing BHV1530-101 study will be featured in an oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026), a leading international forum for early-phase oncology drug development.

First-in-class FGFR3 ADC: BHV-1530

Citi reiterates buy rating on Biohaven Pharma amid rival's trial pause

Fri, 18 Sep 2026 05:17:10 -0400

Citi analyst Samantha Semenkow reiterated a Buy rating and $17.00 price target on Biohaven Pharma (NYSE: BHVN).
The call follows competitor Xenon's decision to voluntarily pause new enrollment in its ongoing trials for major depressive disorder and bipolar depression after identifying neuropsychiatric adverse events in a larger psychiatry dataset of its drug azetukalner, including dizziness, somnolence, confusion, and psychosis-related events.
Semenkow noted that Biohaven's drug opakalim has shown different tolerability data, with updated open-label extension data showing somnolence and dizziness rates of 3% and 4%, respectively, and a 95% patient rollover rate into the extension study. Biohaven is not pursuing major depressive

Form 4 Biohaven Ltd. For: Sep 15 Filed by: Gentile Kimberly

Thu, 17 Sep 2026 18:15:00 -0400
si-local-file:///var/storage/secattach/20260917/27077036.html

H.C. Wainwright Reiterates Neutral Rating on Biohaven Pharma (BHVN)

Fri, 11 Sep 2026 06:59:28 -0400

H.C. Wainwright analyst Douglas Tsao reiterated a Neutral rating and $10.00 price target on Biohaven Pharma (NYSE: BHVN).
The analyst commented: "Today, Biohaven disclosed in an 8-K that the FDA issued a partial clinical hold on September 4 pausing new patient enrollment across the opakalim (BHV-7000) program after nonclinical testing identified a metabolite with uncertain relevance to humans. The hold applies only to new enrollment, and dosing continues for the more than 600 patients already randomized across the program. BHV7000-303, the fully enrolled pivotal focal-epilepsy study, remains on track for top-line data in the second half of 2026. Dosing in the